XALBREGO
Live / Applied — Non-final action mailed (as of 04 Mar 2026)
What this means for you
Not registered yet, but its 17 Dec 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99553124
- Mark type
- Stylized text
- Filed
- 17 Dec 2025
- Attorney of record
- Elsa D. Lemoine
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for use in the treatment of cancer, oncology, tumors, solid and hematological tumors and growths, hematological and hemolytic diseases and disorders, including bone, joint, vertebral column, intestine, colon, prostate, pancreatic, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders, including castration resistant prostate cancer; Pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders; Pharmaceutical preparations for use in the treatment of metastatic diseases; Pharmaceutical preparations for treating metabolic diseases and disorders; Pharmaceutical preparations for treating inflammatory and autoimmune diseases and diseases; Pharmaceutical preparations for treating or preventing cardiovascular and cerebrovascular diseases and disorders; Pharmaceutical preparations
Owner
- Amgen Inc., Thousand Oaks, CA, US
Prosecution history
- 08 Mar 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 08 Mar 2026 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 04 Mar 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 04 Mar 2026 — NON-FINAL ACTION E-MAILED
- 04 Mar 2026 — NON-FINAL ACTION WRITTEN
- 02 Mar 2026 — ASSIGNED TO EXAMINER
- 17 Dec 2025 — APPLICATION FILING RECEIPT MAILED
- 17 Dec 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 17 Dec 2025 — NEW APPLICATION ENTERED